Lasa Supergenerics Limited announces Q3 & 9MFY20 results
MUMBAI: Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain have announced its financial results for the third quarter and nine months ended on December 31st, 2019.
Q3FY20 performance overview compared with Q3FY19
9MFY20 Performance Overview
For the quarter ended December 31st, 2019
Total Income for the quarter ended December 31st, 2019 (Q3FY20) at Rs. 39.29 crores.
The Company reported Earnings Before Interest, Tax, Depreciation, and Amortization (EBITDA) of Rs. 8.16 crore in Q3FY20, as against Rs 7.51 crore in Q2FY20; up 8.7%. The Company’s EBITDA margin improved from 18.58% in Q3FY19 to 20.77% in Q3FY20.
The Company reported a healthy PAT margin of 6.55% and PAT stood at Rs. 2.57 crore for Q3FY20, as
compared to a loss of Rs. 5.28 crore in the corresponding quarter of last fiscal.
Standalone: Earnings per share (EPS for the quarter ended Q3FY20
stood at Rs. 0.89 as compared to Rs. -0.20 in Q2FY20
For nine months ended December 31st, 2019
Total Income for the 9MFY20 ended December 31st, 2019at Rs. 118.69 crore. The Company reported Earnings Before Interest, Tax, Depreciation, and Amortization (EBITDA) of Rs. 20.72 crore in 9MFY20, as against Rs 8.04 crore in 9MFY19; up 157.7%. The Company’s EBITDA margin improved from 6.30% in 9MFY19 to 17.46% in 9MFY20.
The Company reported a PAT of Rs. 1.05 crore for 9MFY20, as
compared to a loss of Rs. 10.23crore in the corresponding period last fiscal.
The Company’s 9MFY20 PAT margin stood at a robust 0.89%, as against -8.01% in 9MFY19.
Commenting on the performance, Dr. Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said “The Company is making progress considering the tough market conditions. Our collective efforts to reduce the finance costs and bring down the working capital cycle is visible and will be a sustained exercise. Rs 36.40 crores from our borrowings have been drastically retired; the working capital cycle has dramatically improved from the past. Benzimidazole Anthalmetics continues to be front product segment and we continue to see strong growth potential in the animal healthcare market in India”
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Sign me up for the newsletter!
Notify me of follow-up comments by email.
Notify me of new posts by email.
2014 The Global Indian New Network (TGINN)